Wird geladen...
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
INTRODUCTION: Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm’s macroglobulinemia. Ibrutinib has an increased risk of atrial fibrillation but the mechanism is...
Gespeichert in:
| Veröffentlicht in: | PLoS One |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Public Library of Science
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6382095/ https://ncbi.nlm.nih.gov/pubmed/30785921 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0211228 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|